Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > ORGANIZATION
ORGANIZATION
- MHLW to Announce 14 New Examples of Approved Off-Label Drug Use Based on 1980 Notification in Near Future
September 26, 2012
- Risk for 7 Main Diseases Increases at Age 63: Anti-Aging Laboratory
September 25, 2012
- JPA Issues Notice on Prohibition of Dispensing Point Services, “Not Intended as Transitional Measure”
September 25, 2012
- Wholesale Industry FTC’s Liaison Conference on Ending Provision of Free Benefits and Labor to Hold 1st Meeting in October
September 25, 2012
- MHLW Reports Results of Analysis of “Close-Call” Incidents at Pharmacies with Generics
September 24, 2012
- Mr Hayashi of OPIR Stresses Need for Approval and Reimbursement of More Companion Diagnostics
September 21, 2012
- Dr Fukuda Lays Out 4 Options for HTA Introduction in Drug Pricing
September 20, 2012
- Anti-Japanese Demonstrations in China Have Had “Absolutely No Effect” on Takeda: President Hasegawa
September 20, 2012
- Maker FTC Bans Drink Donations at Academic Conferences
September 19, 2012
- Iyakuhin Renmei to Break Up to Create Unified Pharmaceutical Industry Labor Union
September 14, 2012
- 35% of Domestic Drug Makers Do Not Conduct First-in-Human Trials in Japan: JPMA Survey
September 5, 2012
- Dr Teshirogi of JPMA Comments on Govt’s Efforts to Promote Regulatory Science; Expresses Concerns About Japan’s Future as Drug-Originating Country
September 5, 2012
- Total Number of MRs Up 4.3% at 63,875, Marking Largest Number in History: MR White Paper
September 5, 2012
- JGA Fails to Achieve Goal of Eliminating “Out-of-Stock” Products Yet Again
August 31, 2012
- Generic Market Share at 25.3% in April-June; Marks Largest Increase: JGA
August 28, 2012
- MHLW Must Present Thorough Explanation If It Insists on Lawmaker-Initiated Bill to Establish 3rd-Party Organization: Yakuhiren
August 28, 2012
- AJD Prioritize Brand Unification of Generic Drugs
August 27, 2012
- Wholesaler’s Operating Profit Margin Improves to 0.31%, Yet Far Cry from FY2007 Level: JPWA
August 10, 2012
- PI Forum to Make Proposals to Promote R&D, Make Pharmaceuticals Japan’s Key Industry: Chairman Toyoda
August 9, 2012
- JPMA Calls for Maintenance or Expansion of R&D Tax Credit System at METI Hearings
August 6, 2012
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…